S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
MarketBeat Week in Review – 9/25 - 9/29
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
The gold catalyst we've waited for (Ad)
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
MarketBeat Week in Review – 9/25 - 9/29
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
The gold catalyst we've waited for (Ad)
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
MarketBeat Week in Review – 9/25 - 9/29
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
The gold catalyst we've waited for (Ad)
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
MarketBeat Week in Review – 9/25 - 9/29
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
The gold catalyst we've waited for (Ad)
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home

Legend Biotech (LEGN) Stock Forecast, Price & News

$67.17
-0.14 (-0.21%)
(As of 09/29/2023 ET)
Compare
Today's Range
$66.72
$68.23
50-Day Range
$63.16
$76.50
52-Week Range
$37.30
$77.32
Volume
525,950 shs
Average Volume
442,805 shs
Market Capitalization
$11.09 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$80.90

Legend Biotech MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.87 Rating Score
Upside/​Downside
20.4% Upside
$80.90 Price Target
Short Interest
Bearish
4.37% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.93mentions of Legend Biotech in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.60) to ($1.61) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.57 out of 5 stars

Medical Sector

893rd out of 972 stocks

Pharmaceutical Preparations Industry

412th out of 444 stocks


LEGN stock logo

About Legend Biotech (NASDAQ:LEGN) Stock

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia , gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. Legend Biotech Corporation was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

LEGN Price History

LEGN Stock News Headlines

Legend Biotech: Working On Supply Issues
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
Legend Biotech (LEGN) Receives a Buy from Barclays
Q2 2023 Legend Biotech Corp Earnings Call
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
BTIG Keeps Their Buy Rating on Legend Biotech (LEGN)
Piper Sandler Reaffirms Their Buy Rating on Legend Biotech (LEGN)
Expert Ratings for Legend Biotech
Legend Biotech's Story Is Still Playing Out
Piper Sandler Sticks to Their Buy Rating for Legend Biotech (LEGN)
See More Headlines
Receive LEGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Legend Biotech and its competitors with MarketBeat's FREE daily newsletter.

LEGN Company Calendar

Last Earnings
8/15/2023
Today
9/30/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:LEGN
Fax
N/A
Employees
1,390
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$80.90
High Stock Price Forecast
$92.00
Low Stock Price Forecast
$64.00
Forecasted Upside/Downside
+20.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.87
Research Coverage
15 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$164.66 million
Book Value
$4.54 per share

Miscellaneous

Free Float
165,034,000
Market Cap
$11.09 billion
Optionable
Not Optionable
Beta
0.02
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Dr. Ying Huang Ph.D. (Age 50)
    CEO & Director
  • Ms. Lori A. Macomber CPA (Age 52)
    Chief Financial Officer
  • Dr. Guowei Fang Ph.D.
    Chief Scientific Officer & Head of Bus. Devel.
  • Joanne Choi
    Sr. Mang. of Investor Relations
  • Deborah Wong
    Exec. Director of Strategic Marketing & Corp. Communications
  • Ms. Elaine Qian
    VP & Global Head of HR
  • Ms. Liz Gosen
    Sr. VP of Technical Operations
  • Dr. Yuhong Qiu Ph.D.
    Sr. VP of Global Regulatory Affairs
  • Mr. Steven J. Gavel
    Sr. VP of Commercial Devel., US & Europe
  • Mr. Alan Kick
    Sr. VP of Global Quality













LEGN Stock - Frequently Asked Questions

Should I buy or sell Legend Biotech stock right now?

15 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Legend Biotech in the last twelve months. There are currently 2 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" LEGN shares.
View LEGN analyst ratings
or view top-rated stocks.

What is Legend Biotech's stock price forecast for 2023?

15 brokers have issued 1 year target prices for Legend Biotech's shares. Their LEGN share price forecasts range from $64.00 to $92.00. On average, they anticipate the company's share price to reach $80.90 in the next twelve months. This suggests a possible upside of 20.4% from the stock's current price.
View analysts price targets for LEGN
or view top-rated stocks among Wall Street analysts.

How have LEGN shares performed in 2023?

Legend Biotech's stock was trading at $49.92 at the beginning of 2023. Since then, LEGN shares have increased by 34.6% and is now trading at $67.17.
View the best growth stocks for 2023 here
.

How were Legend Biotech's earnings last quarter?

Legend Biotech Co. (NASDAQ:LEGN) posted its earnings results on Tuesday, August, 15th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.36) by $0.21. The business earned $73.30 million during the quarter, compared to analysts' expectations of $56.64 million. The business's quarterly revenue was up 510.8% compared to the same quarter last year.

What other stocks do shareholders of Legend Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Legend Biotech investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), CrowdStrike (CRWD), Lam Research (LRCX), ServiceNow (NOW), Peloton Interactive (PTON), QUALCOMM (QCOM), Applied Materials (AMAT), DocuSign (DOCU) and Etsy (ETSY).

When did Legend Biotech IPO?

(LEGN) raised $350 million in an initial public offering on Friday, June 5th 2020. The company issued 18,400,000 shares at $18.00-$20.00 per share. Morgan Stanley, J.P. Morgan Securities and Jefferies served as the underwriters for the IPO.

What is Legend Biotech's stock symbol?

Legend Biotech trades on the NASDAQ under the ticker symbol "LEGN."

How do I buy shares of Legend Biotech?

Shares of LEGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Legend Biotech's stock price today?

One share of LEGN stock can currently be purchased for approximately $67.17.

How much money does Legend Biotech make?

Legend Biotech (NASDAQ:LEGN) has a market capitalization of $11.09 billion and generates $164.66 million in revenue each year.

How many employees does Legend Biotech have?

The company employs 1,390 workers across the globe.

How can I contact Legend Biotech?

Legend Biotech's mailing address is 2101 COTTONTAIL LANE, SOMERSET NJ, 08873. The official website for the company is www.legendbiotech.com. The company can be reached via phone at 732-317-5050 or via email at investor@legendbiotech.com.

This page (NASDAQ:LEGN) was last updated on 10/1/2023 by MarketBeat.com Staff

My Account -